Anemia
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Anemia is a highly competitive landscape with 221 programs across 84 companies. The most active players are Prolong Pharmaceuticals, Sunshine Lake Pharma Co., Ltd., Nanogen Pharmaceutical Biotechnology Joint Stock Company. 40 therapies are approved with 58 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Prolong Pharmaceuticals
1 program
Sunshine Lake Pharma Co., Ltd.
1 program
Nanogen Pharmaceutical Biotechnology Joint Stock Company
1 program
Eastern Cooperative Oncology Group
1 program
Mario Negri Institute for Pharmacological Research
1 program
TME Pharma AG
2 programs
Pipeline
Programs by Phase
Analysis
Modality Breakdown
94%
Small molecule
233 of 247 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 247 classified programs, each share of the total. Modality classified for 100% of 273 pipeline programs.
Analysis
Trial Status
406
clinical trials
Clinical Trials
Trial Activity
406 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)